Lexaria Bioscience Corp. (LEXX)
Automate Your Wheel Strategy on LEXX
With Tiblio's Option Bot, you can configure your own wheel strategy including LEXX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LEXX
- Rev/Share 0.0337
- Book/Share 0.2823
- PB 2.4586
- Debt/Equity 0.021
- CurrentRatio 3.9021
- ROIC -2.1569
- MktCap 13503039.0
- FreeCF/Share -0.5339
- PFCF -1.3822
- PE -1.1984
- Debt/Assets 0.0173
- DivYield 0
- ROE -1.4935
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Lexaria Releases Annual Letter from the CEO
Published: January 12, 2026 by: TheNewswire
Sentiment: Neutral
Kelowna, British Columbia – TheNewswire - January 12, 2026 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW), (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to provide this Annual Letter from its Chief Executive Officer (“CEO”) Richard Christopher as a strategic update to all stakeholders. CEO Letter to Stakeholders
Read More
Lexaria Releases Annual Letter from the CEO
Published: January 12, 2026 by: Accesswire
Sentiment: Neutral
KELOWNA, BC / ACCESS Newswire / January 12, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this Annual Letter from its Chief Executive Officer ("CEO") Richard Christopher as a strategic update to all stakeholders. CEO Letter to Stakeholders Dear Fellow Stakeholders, I'm truly honored to deliver Lexaria's Annual Letter from the CEO following my first full year in the position.
Read More
Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4
Published: December 30, 2025 by: Accesswire
Sentiment: Neutral
KELOWNA, BC / ACCESS Newswire / December 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following additional secondary and exploratory endpoint final results update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the "Study" or the "Lexaria Study"), recently completed in Australia, focusing on 4 DehydraTECH™ ("DHT") study arms relative to the Rybelsus® control study arm. "We are pleased to report additional data from our first Phase 1b clinical study," stated Richard Christopher, CEO of Lexaria.
Read More
Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4
Published: December 30, 2025 by: TheNewswire
Sentiment: Neutral
Kelowna, British Columbia – December 30, 2025 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, provides the following additional secondary and exploratory endpoint final results update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the “ Study ” or the “ Lexaria Study ”), recently completed in Australia, focusing on 4 DehydraTECH™ ( “DHT” ) study arms relative to the Rybelsus® control study arm. “We are pleased to report additional data from our first Phase 1b clinical study,” stated Richard Christopher, CEO of Lexaria. “It adds to a …
Read More
Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4
Published: December 23, 2025 by: TheNewswire
Sentiment: Neutral
DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus
Read More
Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4
Published: December 23, 2025 by: Accesswire
Sentiment: Neutral
DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus® DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus® Recent financings create runway for prospective new 2026 development opportunities KELOWNA, BC / ACCESS Newswire / December 23, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following final primary and major secondary efficacy endpoint results update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the " Study " or the " Lexaria Study "), recently completed in Australia, focusing on 4 DehydraTECH ® ( "DHT" ) study …
Read More
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
Published: November 12, 2025 by: TheNewswire
Sentiment: Neutral
Kelowna, British Columbia – November 12, 2025 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update on the Material Transfer Agreement (“MTA”) originally entered into on September 4, 2024 with a pharmaceutical company (“PharmaCO”) to evaluate Lexaria's DehydraTECH TM technology in a pre-clinical setting. The original agreement has been extended through April 30, 2026, to accommodate time needed for PharmaCO's receipt and review of the full dataset from Lexaria's Australian study, at which time further information will be provided. This allows the two parties to continue …
Read More
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
Published: November 12, 2025 by: Accesswire
Sentiment: Neutral
KELOWNA, BC / ACCESS Newswire / November 12, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update on the Material Transfer Agreement ("MTA") originally entered into on September 4, 2024 with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's DehydraTECHTM technology in a pre-clinical setting. The original agreement has been extended through April 30, 2026, to accommodate time needed for PharmaCO's receipt and review of the full dataset from Lexaria's Australian study, at which time further information will be provided.
Read More
Lexaria Bioscience Corp. Provides Strategic Update
Published: October 09, 2025 by: Accesswire
Sentiment: Neutral
Strategic Business Development Advisory Firm Engaged To Support New Business Development Activities Lexaria Awarded 4 New Patents KELOWNA, BC / ACCESS Newswire / October 9, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide the following strategic business update. For several years, Lexaria has been validating the applicability of its patented DehydraTECH technology across a number of sectors within the pharmaceutical industry.
Read More
Lexaria Bioscience Corp. Provides Strategic Update
Published: October 09, 2025 by: TheNewswire
Sentiment: Neutral
Strategic Business Development Advisory Firm Engaged To Support New Business Development Activities
Read More
Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain
Published: September 19, 2025 by: TheNewswire
Sentiment: Neutral
Enhanced Brain Biodistribution of GLP-1 Drugs May Be Related to Improvements in Safety and Efficacy Kelowna, British Columbia – September 19, 2025 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms, is pleased to announce successful results from its fluorescently tagged semaglutide (“ FTS ”) rodent biodistribution study (the “ Study ”).
Read More
Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference
Published: August 27, 2025 by: TheNewswire
Sentiment: Neutral
Kelowna, British Columbia – August 27, 2025 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms, today announced that it will participate in the 27 th Annual H.C. Wainwright Global Investment Conference, taking place September 8 th through September 10 th , 2025. Richard Christopher, Chief Executive Officer of Lexaria Bioscience, will deliver a company presentation and be available for one-on-one investor meetings throughout the event. His presentation will be available for remote viewing anytime after 7:00 AM EST on September 5 th at this …
Read More
Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference
Published: August 27, 2025 by: Accesswire
Sentiment: Neutral
KELOWNA, BC / ACCESS Newswire / August 27, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it will participate in the 27th Annual H.C. Wainwright Global Investment Conference, taking place September 8th through September 10th, 2025.
Read More
Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone
Published: August 14, 2025 by: TheNewswire
Sentiment: Neutral
Kelowna, British Columbia – TheNewswire - August 14, 2025 – Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms, is pleased to announce that its Contract Research Organization (“ CRO ”) has completed the important study milestone known as last patent last visit (“ LPLV ”) in Lexaria's Phase 1b glucagon-like peptide-1 (“ GLP-1 ”) study in Australia, GLP-1-H24-4 (the “ Study ”). “We are delighted that this important milestone has been achieved on schedule, concluding all patient dosing and clinical testing in our Study,” said John Docherty, …
Read More
Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone
Published: August 14, 2025 by: Accesswire
Sentiment: Neutral
KELOWNA, BC / ACCESS Newswire / August 14, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that its Contract Research Organization ("CRO") has completed the important study milestone known as last patent last visit ("LPLV") in Lexaria's Phase 1b glucagon-like peptide-1 ("GLP-1") study in Australia, GLP-1-H24-4 (the "Study"). "We are delighted that this important milestone has been achieved on schedule, concluding all patient dosing and clinical testing in our Study," said John Docherty, Lexaria's President and CSO.
Read More
GLP-1 "Arms Race" Broadens to Include Dozens of Companies
Published: August 06, 2025 by: Accesswire
Sentiment: Neutral
Lexaria highlights DehydraTECH's adverse events improvement opportunity KELOWNA, BC / ACCESS Newswire / August 6, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following glucagon-like peptide-1 ("GLP-1") and obesity industry update. The market for obesity and diabetes control drugs such as GLP-1 is growing at faster rates than nearly anyone originally anticipated, with revenues now expected to exceed $150 billion by 2030.
Read More
Lexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 Study
Published: July 28, 2025 by: TheNewswire
Sentiment: Neutral
DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus
Read More
Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study
Published: July 28, 2025 by: Accesswire
Sentiment: Neutral
DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus® DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus® DehydraTECH-GLP-1 study arms evidencing patient safety and tolerability consistent with the primary study endpoint KELOWNA, BC / ACCESS Newswire / July 28, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following partial 8-week positive interim results update on the phase 1b, 12-week chronic study GLP-1-H24-4 (the "Study" or the "Lexaria Study"), currently underway in Australia, focusing on the DehydraTECH ("DHT") glucagon-like peptide-1 ("GLP-1") study arms 2 and …
Read More
Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry
Published: July 23, 2025 by: TheNewswire
Sentiment: Neutral
The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effects DehydraTECH reduces side effects and could support patient retention and further industry growth
Read More
Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry
Published: July 23, 2025 by: Accesswire
Sentiment: Neutral
The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effects DehydraTECH reduces side effects and could support patient retention and further industry growth DehydraTECH is the only technology publicly disclosed for its ability to reduce side effects in all 3 of the top GLP-1 drugs currently sold in the world today: semaglutide, tirzepatide, and liraglutide KELOWNA, BC / ACCESS Newswire / July 23, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following glucagon-like peptide-1 ("GLP-1") strategic update as the …
Read More
Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide
Published: June 23, 2025 by: Accesswire
Sentiment: Neutral
New patents received for the treatment of epilepsy and for the sublingual delivery of nicotine KELOWNA, BC / ACCESS Newswire / June 23, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that it has received 2 new international patents. This now brings Lexaria's total worldwide patent portfolio to 50.
Read More
Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide
Published: June 23, 2025 by: TheNewswire
Sentiment: Neutral
New patents received for the treatment of epilepsy and for the sublingual delivery of nicotine Kelowna, British Columbia – June 23, 2025 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that it has received 2 new international patents. This now brings Lexaria's total worldwide patent portfolio to 50.
Read More
Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule
Published: June 11, 2025 by: TheNewswire
Sentiment: Neutral
Oral DehydraTECH-liraglutide showed a pronounced reduction in adverse events (“AEs”) as compared to injected liraglutide (Saxenda®) Lexaria has now demonstrated, in distinct human clinical studies, clear reductions in AEs utilizing its patented DehydraTECH technology with all of the three major GLP-1 drugs sold in the world today: liraglutide, semaglutide and tirzepatide
Read More
Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule
Published: June 11, 2025 by: Accesswire
Sentiment: Neutral
Oral DehydraTECH-liraglutide showed a pronounced reduction in adverse events (“AEs”) as compared to injected liraglutide (Saxenda(R)) Lexaria has now demonstrated, in distinct human clinical studies, clear reductions in AEs utilizing its patented DehydraTECH technology with all of the three major GLP-1 drugs sold in the world today: liraglutide, semaglutide and tirzepatide KELOWNA, BC / ACCESS Newswire / June 11, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that human study GLP-1-H25-5 (the "Study") which compared oral capsules of DehydraTECH-liraglutide to injected Saxenda®-branded liraglutide has been successfully completed …
Read More
Lexaria Attending BIO International Convention
Published: June 05, 2025 by: TheNewswire
Sentiment: Neutral
Biotechnology Sector's Premier Strategic Partnering Event Kelowna, British Columbia – June 5, 2025 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that its Chief Executive Officer and President and Chief Scientific Officer will be attending the BIO International Convention (“BIO”) in Boston, June 16-19.
Read More
Lexaria Attending BIO International Convention
Published: June 05, 2025 by: Accesswire
Sentiment: Neutral
Biotechnology Sector's Premier Strategic Partnering Event KELOWNA, BC / ACCESS Newswire / June 5, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that its Chief Executive Officer and President and Chief Scientific Officer will be attending the BIO International Convention ("BIO") in Boston, June 16-19. With over 1,500 exhibitors and 20,000 attendees, BIO is the largest biotechnology convention in the world.
Read More
Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company
Published: May 12, 2025 by: Accesswire
Sentiment: Neutral
KELOWNA, BC / ACCESS Newswire / May 12, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update on corporate developments. Lexaria previously announced, on September 3, 2024, that it had entered into a Material Transfer Agreement ("MTA") with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's DehydraTECHTM technology in a pre-clinical setting.
Read More
Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company
Published: May 12, 2025 by: TheNewswire
Sentiment: Neutral
Kelowna, British Columbia – TheNewswire - May 12, 2025 - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update on corporate developments. Lexaria previously announced, on September 3, 2024, that it had entered into a Material Transfer Agreement (“MTA”) with a pharmaceutical company (“PharmaCO”) to evaluate Lexaria's DehydraTECH TM technology in a pre-clinical setting.
Read More
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology
Published: April 23, 2025 by: Accesswire
Sentiment: Neutral
Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industry Lexaria's technology could enhance performance and lower side effects KELOWNA, BC / ACCESS Newswire / April 23, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following glucagon-like peptide-1 ("GLP-1") strategic update following important industry developments reported both by Pfizer® Inc. and by Eli Lilly and Company®. Nearly all of the world's top pharmaceutical companies are racing to develop new oral GLP-1 drugs, including: Amgen®, AstraZenca, Eli Lilly, Merck®, Novo Nordisk®, Pfizer®, and Roche®.
Read More
Lexaria's Human GLP-1 Study #5 Begins Dosing
Published: April 02, 2025 by: Accesswire
Sentiment: Neutral
Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutide Study will investigate Pharmacokinetics and Safety KELOWNA, BC / ACCESS Newswire / April 2, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that dosing has begun as scheduled in its human study GLP-1-H25-5 (the "Study") that is comparing oral DehydraTECH-liraglutide to injected Saxenda®-branded liraglutide. On November 20, 2024, Lexaria reported on an earlier 12-week study in rodents which showed that with unlimited food available, oral DehydraTECH-liraglutide demonstrated a 5.88% weight reduction and an 11.54% blood sugar …
Read More
About Lexaria Bioscience Corp. (LEXX)
- IPO Date 2021-01-12
- Website https://www.lexariabioscience.com
- Industry Biotechnology
- CEO Richard C. Christopher
- Employees 7